Lexeo Therapeutics (NASDAQ:LXEO) Raised to “Strong-Buy” at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by Chardan Capital to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and an average target price of $18.75.

Lexeo Therapeutics Stock Up 0.9%

Lexeo Therapeutics stock opened at $4.35 on Tuesday. The business has a 50 day moving average price of $4.71 and a two-hundred day moving average price of $5.84. Lexeo Therapeutics has a 12 month low of $4.03 and a 12 month high of $10.99. The stock has a market cap of $341.57 million, a price-to-earnings ratio of -3.00 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, analysts expect that Lexeo Therapeutics will post -1.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the sale, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the sale, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. The trade was a 21.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 62,204 shares of company stock valued at $280,089. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Lexeo Therapeutics by 6.1% in the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after buying an additional 1,626 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares during the last quarter. Intech Investment Management LLC grew its holdings in Lexeo Therapeutics by 19.5% during the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after acquiring an additional 2,317 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Lexeo Therapeutics by 25.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock valued at $118,000 after acquiring an additional 2,427 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.